FOLFIRINOX De‐Escalation in Advanced Pancreatic Cancer: A Multicenter Real‐Life Study

Background Our study describes the feasibility and efficacy of a first‐line FOLFIRINOX (5‐fluorouracil [5FU], folinic acid, irinotecan, and oxaliplatin) induction chemotherapy (CT) followed by de‐escalation as a maintenance strategy for advanced pancreatic cancer. Materials and Methods This multicenter retrospective study was conducted from January 2011 to December 2018. FOLFIRINOX de‐escalation was defined as stopping oxaliplatin and/or irinotecan after at least four cycles of FOLFIRINOX, without evidence of disease progression. Maintenance schedules were fluoropyrimidine monotherapy (intravenous or oral [capecitabine]), FOLFOX (5FU, oxaliplatin), or FOLFIRI (5FU, irinotecan). Primary endpoint was overall survival (OS). Secondary endpoints were first progression‐free survival (PFS1), second progression‐free survival (PFS2), and toxicity. Results Among 321 patients treated with FOLFIRINOX, 147 (45.8%) were included. Median OS was 16.1 months (95% confidence interval [CI], 13.7–20.3) and median PFS1 was 9.4 months (95% CI, 8.5–10.4). The preferred maintenance regimen was FOLFIRI in 66 (45%) patients versus 5FU monotherapy in 52 (35%) and FOLFOX in 25 (17%) patients. Among 118 patients who received maintenance CT with FOLFIRI or 5FU, there was no difference in PFS1 (median, 9.0 vs. 10.1 months, respectively; p = .33) or OS (median, 16.6 vs. 18.7 months; p = .86) between the two maintenance regimens. Reintroduction of FOLFIRINOX was performed in 20.2% of patients, with a median PFS2 of 2.8 months (95% CI, 2.0–22.3). The rates of grade 3–4 toxicity were significantly higher with FOLFIRI maintenance CT than with 5FU (41% vs. 22%; p = .03), especially for neuropathy (73% vs. 9%). Conclusion 5FU monotherapy maintenance appeared to be as effective as FOLFIRI, in a FOLFIRINOX de‐escalation strategy, which is largely used in France. Implications for Practice FOLFIRINOX de‐escalation and maintenance is a feasible strategy in advanced pancreatic cancer that decreases chemotherapy toxicity to improve both survival and quality of life. Survivals in patients with maintenance therapy are clinically meaningful. Fluoropyrimidine monotherapy maintenance seems to be as efficient as FOLFIRI and should be a reference arm in future pancreatic cancer maintenance trials. This article provides a descriptive overview of the feasibility and efficacy results of therapeutic de‐escalation of FOLFIRINOX in patients with metastatic pancreatic cancer.